Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis

BACKGROUND: The present study evaluated the relative survival benefits associated with enasidenib and current standard of care (SoC) therapies for patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and an isocitrate dehydrogenase 2 (IDH2) mutation who are ineligible for hematopoiet...

Descripción completa

Detalles Bibliográficos
Autores principales: de Botton, Stéphane, Brandwein, Joseph M., Wei, Andrew H., Pigneux, Arnaud, Quesnel, Bruno, Thomas, Xavier, Legrand, Ollivier, Recher, Christian, Chantepie, Sylvain, Hunault‐Berger, Mathilde, Boissel, Nicolas, Nehme, Salem A., Frattini, Mark G., Tosolini, Alessandra, Marion‐Gallois, Roland, Wang, Jixian J., Cameron, Chris, Siddiqui, Muhaimen, Hutton, Brian, Milkovich, Gary, Stein, Eytan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446562/
https://www.ncbi.nlm.nih.gov/pubmed/34427990
http://dx.doi.org/10.1002/cam4.4182

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446562/
https://www.ncbi.nlm.nih.gov/pubmed/34427990
http://dx.doi.org/10.1002/cam4.4182

Ejemplares similares